Gensco Laboratories Supports World Arthritis Day on October 12, 2015
Gensco Laboratories, a specialty pharmaceutical company, has recently introduced a new transdermal prescription medication that provides rapid relief at the first sign of an acute gout flare, ColciGel®, indicated for the treatment and prophylaxis of acute gout flares in adults. ColciGel® is easy to apply directly on the site of pain and each bottle has Metered Dose Technology (MDose™) which dispenses the exact amount of transdermal medication.
Miami, FL, October 12, 2015 --(PR.com)-- Today, October 12, is recognized as World Arthritis Day, a global initiative bringing people together to raise awareness of rheumatic and musculoskeletal diseases (RMDs), influence public policy and inform those living with RMDs of the support network available to them.
Gout is the most common form of inflammatory arthritis, however only 37% of Americans know that gout is a type of arthritis. There are also many other misconceptions about gout. In fact, one (1) in five (5) say they do not know what gout is at all, and six (6) in ten (10) admit to not knowing that gout is a chronic, life-long disease. Gout affects more than 8.3 million Americans and is typically seen in men between 40-55 years of age. To reduce risk for gout and future flares, it is important to maintain a healthy serum uric acid level of 6.0 mg/dL and ask your doctor for a routine blood test every six months.
Learn more about the Gout & Uric Acid Education Society’s "Go for 6" campaign by visiting www.gouteducation.org.
Gensco Laboratories, a specialty pharmaceutical company, has recently introduced a new transdermal prescription medication that provides rapid relief at the first sign of an acute gout flare, ColciGel®, indicated for the treatment and prophylaxis of acute gout flares in adults. ColciGel® is easy to apply directly on the site of pain and each bottle has Metered Dose Technology (MDose™) which dispenses the exact amount of transdermal medication.
“Our focus at Gensco is to utilize our resources to develop unique drug delivery systems and manufacture quality medications which help prescribers, healthcare providers and patients improve health,” said Carlos Alfaras, CEO of Gensco Laboratories. “We also support the voice of our partners to educate the public on available educational sources and solutions for patients in pain.”
About ColciGel®: ColciGel® is the only transdermal gel prescription available to treat the symptoms of acute gout flares. Available only through specialty pharmacies, this revolutionary gel penetrates the dermal layer at the local site of application to decrease the pain associated with gout flares within a few hours.
To learn more about ColciGel®, please visit www.colcigel.com. To learn more about Gensco products, visit www.genscolabs.com.
Media Contact:
Randi Press | Patricia Beitler
Gensco Laboratories
P: 305.503.3055
press@genscolabs.com
Gout is the most common form of inflammatory arthritis, however only 37% of Americans know that gout is a type of arthritis. There are also many other misconceptions about gout. In fact, one (1) in five (5) say they do not know what gout is at all, and six (6) in ten (10) admit to not knowing that gout is a chronic, life-long disease. Gout affects more than 8.3 million Americans and is typically seen in men between 40-55 years of age. To reduce risk for gout and future flares, it is important to maintain a healthy serum uric acid level of 6.0 mg/dL and ask your doctor for a routine blood test every six months.
Learn more about the Gout & Uric Acid Education Society’s "Go for 6" campaign by visiting www.gouteducation.org.
Gensco Laboratories, a specialty pharmaceutical company, has recently introduced a new transdermal prescription medication that provides rapid relief at the first sign of an acute gout flare, ColciGel®, indicated for the treatment and prophylaxis of acute gout flares in adults. ColciGel® is easy to apply directly on the site of pain and each bottle has Metered Dose Technology (MDose™) which dispenses the exact amount of transdermal medication.
“Our focus at Gensco is to utilize our resources to develop unique drug delivery systems and manufacture quality medications which help prescribers, healthcare providers and patients improve health,” said Carlos Alfaras, CEO of Gensco Laboratories. “We also support the voice of our partners to educate the public on available educational sources and solutions for patients in pain.”
About ColciGel®: ColciGel® is the only transdermal gel prescription available to treat the symptoms of acute gout flares. Available only through specialty pharmacies, this revolutionary gel penetrates the dermal layer at the local site of application to decrease the pain associated with gout flares within a few hours.
To learn more about ColciGel®, please visit www.colcigel.com. To learn more about Gensco products, visit www.genscolabs.com.
Media Contact:
Randi Press | Patricia Beitler
Gensco Laboratories
P: 305.503.3055
press@genscolabs.com
Contact
Gensco Labs
Patricia Beitler
305-503-3055
genscolabs.com
Patricia Beitler
305-503-3055
genscolabs.com
Contact
Multimedia
Categories